Bayer’s Rally Hits a Technical Speed Bump as a Transatlantic Pricing War Heats Up
Published on 07/23/2026 at 19:12 | Redaktion boerse-global.de
The Bayer share has pulled back from its recent record highs, leaving investors to parse whether the summer surge has run its course or is merely catching its breath. After a blistering run that saw the stock rocket from €34.10 to a 52-week peak of €53.92 in just over a month, the shares closed Thursday at €46.22, down 0.84% on the day. That marks a 14% retreat from the July 3 high, a correction that chart watchers say was all but inevitable given the breakneck pace of the advance.
The technical picture tells a story of overheating followed by a natural cooldown. At the peak, the stock had punched clean through the upper Bollinger Band — a classic signal that momentum had become unsustainable. Since then, the 14-day Relative Strength Index has settled back to 50.5, squarely in neutral territory and well clear of the overbought zone that had flashed warning signs. Yet the share still trades roughly 10% above its 50-day moving average of €41.97, suggesting the underlying trend remains intact.
Money flows confirm the pause is orderly rather than panicked. The Chaikin Money Flow indicator, which tracks capital inflows and outflows, remains positive even as it has edged lower during the consolidation. That suggests buyers are still present, just more cautious after the rapid ascent.
A Political Storm Gathers Over Generics
The technical breather coincides with fresh political headwinds. US President Donald Trump announced via Truth Social a plan for staggered special tariffs on generic drugs, set to take effect in summer 2028. The announcement sent a chill through the European pharmaceutical sector, with Bayer among the names caught in the downdraft. For a company already heavily exposed to US regulatory developments, the tariff threat adds another layer of uncertainty.
Should investors sell immediately? Or is it worth buying Bayer?
But the political drama runs deeper than a single social media post. The US launched a Section 301 investigation against Germany in mid-June, accusing Berlin of artificially suppressing drug prices — a practice Trump has labeled "global freeloading." While rivals Boehringer Ingelheim and Merck have opted to offer discounted products on the TrumpRX platform, Bayer has taken a markedly different stance: the Leverkusen-based group is backing the US position and calling for higher medicine prices in Europe.
The EU Commission is now weighing a counter-strategy, warning that the end result could be fewer new drugs reaching the European market. The potential fallout is illustrated by the UK's deal with Washington, which critics say could cost the National Health Service up to €51.5 billion by 2036 and lead to as many as 229,000 additional deaths due to more expensive or restricted care. German Chancellor Friedrich Merz has so far rejected the US demands for higher prices, while the economics ministry has signaled a willingness to engage in talks.
Technical Levels to Watch
Chart analysts have identified several key zones for the near term. The current consolidation band runs from €46.74 to €47.60, marking the first line of support. Should that give way, the next floor sits at €45.41, with the rising 50-day moving average at €43.90 representing a crucial level for the bulls.
Bayer at a turning point? This analysis reveals what investors need to know now.
The Glyphosate Elephant
Despite the recent pullback, the medium-term picture remains striking. The stock is up 60.85% over the past twelve months and has gained 24.89% year-to-date. Much of that advance traces back to the unresolved glyphosate litigation — the same legal saga that ignited the June rally. The share is effectively pricing in expectations around the next round of court rulings, which are expected in the coming weeks. For now, the stock is caught between a technical consolidation that looks healthy and a political environment that is anything but.
Ad
Bayer Stock: New Analysis - 23 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
